Cancer Vaccine

Regulatory T cells may have a role in poor immune response against tumor antigens

Published in Vaccine Weekly, November 27th, 2002

by Maria G. Essig, MS, ELS, senior medical writer - The weak immunogenicity of tumor antigens may be due to regulatory T cells that suppress the response of self-reactive T cells to prevent development of autoimmune disease, according to a report in the Journal of Immunology.

"In mice, depletion of regulatory T cells by antibody therapy leads to more efficient tumor rejection," said Udaya K. Liyanage and colleagues at the Alvin J. Siteman Cancer Center in St. Louis. "Regulatory T cell-medicated suppression of antitumor immune responses may partly explain the poor clinical response to vaccine-based immunotherapy for human cancer."

The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry